15.53 - 236.5
Join Discuss about NVAX with like-minded investors
FB LTHM COUP AMD TTD ZIM RBLX JPM PM Short NET COIN UPST DASH DIS CVS NVAX
83 Replies 7 👍 13 🔥
Next Dividend Date
Novavax, Inc. is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.
CEO: Stanley Erck
HQ: 21 Firstfield Rd Gaithersburg, 20878-1757 Maryland